CTA
EBS icon

Carillon Tower Advisers’s Emergent Biosolutions EBS Stock Holding History

Carillon Tower Advisers’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$36.8M Buy
411,186
+12,521
+3% +$1.15M 0.22% 137
2020
Q3 		$41.2M Buy
398,665
+105,439
+36% +$11.4M 0.55% 33
2020
Q2 		$23.2M Buy
+293,226
New +$21.9M 0.18% 172

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Carillon Tower Advisers's EBS Position: Q4 2020 in Review

Carillon Tower Advisers increased its Emergent Biosolutions (EBS) stake by 3.1% in Q4 2020, buying an estimated $1.15M and bringing the position to 411,186 shares worth $36.8M. The position accounts for 0.22% of the portfolio, ranked #137.

Carillon Tower Advisers first reported a position in EBS in Q2 2020 and has held it in 3 quarters since. The position peaked at $41.2M in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Carillon Tower Advisers held 411,186 shares of Emergent Biosolutions worth $36.8M as of Q4 2020.
  • Carillon Tower Advisers bought 12,521 Emergent Biosolutions shares in Q4 2020, an estimated $1.15M.
  • Emergent Biosolutions made up 0.22% of Carillon Tower Advisers's portfolio in Q4 2020, its #137 holding.
  • Carillon Tower Advisers first reported a position in Emergent Biosolutions in Q2 2020 and has held it in 3 quarters since.
  • Carillon Tower Advisers's Emergent Biosolutions position peaked at $41.2M in Q3 2020.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.